Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life.

OBJECTIVE: This study aimed to evaluate the effects of short-term (60-d) oral supplementation with calcium fructoborate, resveratrol, and their combination on the clinical and biological statuses of subjects with stable angina pectoris. METHODS: A randomized, double-blinded, active-controlled, parallel clinical trial was conducted in three groups of subjects. Of the total number of subjects included in study (n = 166), 87 completed the 60-d test treatment study period and 29 followed in parallel their usual medical care and treatment. The primary outcomes were inflammation biomarkers (high-sensitivity C-reactive protein), left ventricular function markers (N-terminal prohormone of brain natriuretic peptide), and lipid markers (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triacylglycerols). Quality of life was assessed by the Canadian Cardiovascular Society angina class and the number of angina attacks per week. RESULTS: There was a significant decrease of high-sensitivity C-reactive protein in all groups at the 30-d and 60-d visits. This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate), followed by group 2 (resveratrol plus calcium fructoborate, 30.3% at 60 d). The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol (group 1, 59.7% at 60 d) and by calcium fructoborate (group 3, 52.6% at 60 d). However, their combination (group 2) was the most effective and induced a decrease of 65.5%. Lipid markers showed slight changes from baseline in all groups. The improvement in the quality of life was best observed for subjects who received the resveratrol and calcium fructoborate mixture (group 2). CONCLUSION: The results indicate that the combination of resveratrol and calcium fructoborate has beneficial effects in patients with angina

Hybrid technology with microwaves, electron beams and catalysts for VOCs removals.

This work presents a hybrid technology and two hybrid installations (HI-1 and HI-2) for volatile organic compounds (VOCs) removal using successive or simultaneous microwave (MW) irradiation, electron beam (EB) irradiation, and catalytic oxidation. HI-1 is designed for successive EB and MW irradiation with two distinct reactors, both containing a catalyst inside. HI-2 is designed for simultaneous EB and MW irradiation in the same reactor containing a catalyst. Real synergistic effects between non-thermal plasma (NTP) and catalysis were obtained by introducing the catalyst into the irradiation zone, i.e. into the MW reactor EB reactor or into a reactor in which both EB and MW are injected.

SO2 and NOx removal by microwave and electron beam processing.

This work presents a method and a semi-pilot scale installation (SPSI) for the simultaneous SO2 and NOx removal by separate and combined microwave (MW) and electron beam (EB) irradiation. The SPSI consists mainly of the following units: a gaseous mixture preparation system (GMPS), a microwave source (MS) of 2.45 GHz and 4.2 kW maximum output power an electron beam source (EBS) of 1.8 MeVand 10.8 kW maximum output power and a multimode rectangular cavity (MRC), used as reaction chamber in which are injected both MW and EB fields. The most important parameters for high SO2 removal efficiencies obtained by MW technology are water and ammonia concentration, the gaseous mixture temperature during irradiation process and MW power level. The most important parameter for high NOx removal efficiency obtained by MW technology is MW power level. The removal efficiencies obtained by MW processing were up to 95% for SO2 and up to 55% for NOx. The additional use of EB irradiation to MW exposure strongly increases NOx removal efficiencies in comparison with MW exposure only, up to 95%, simultaneously providing very high values for the SO2 removal efficiency, near 100%.